Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had approved this drug for a broad indication opened up a market in the US currently worth over $1bn p.a. – a US partnership deal is expected in 2020. A 2019 trading update showed STX’s performance to be in line with expectations, with £0.6m i
28 Jan 2020
Good demand for Feraccru in Europe
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good demand for Feraccru in Europe
Shield Therapeutics Plc (STX:LON) | 1.2 0 (-7.5%) | Mkt Cap: 9.58m
- Published:
28 Jan 2020 -
Author:
Martin Hall -
Pages:
5
Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had approved this drug for a broad indication opened up a market in the US currently worth over $1bn p.a. – a US partnership deal is expected in 2020. A 2019 trading update showed STX’s performance to be in line with expectations, with £0.6m i